Teva Advances Anti-IL-15 Antibody into Phase 2b for Vitiligo After Promising Early Data
Event summary
- Teva will advance TEV-’408, an anti-IL-15 antibody, into Phase 2b trials for vitiligo in Q4 2026 after encouraging Phase 1b results.
- 75% of patients reported facial vitiligo improvement, with half seeing 'much' or 'very much' improved outcomes at week 24.
- TEV-’408 is designed for quarterly subcutaneous dosing and has shown no safety signals to date.
- $500 million in R&D funding from Royalty Pharma supports the Phase 2b study.
The big picture
Teva’s decision to advance TEV-’408 reflects its strategic shift toward innovative biopharmaceuticals, leveraging its immunology expertise. The Phase 2b trial follows a broader industry trend of targeting IL-15 for autoimmune diseases, with potential applications beyond vitiligo. The $500 million R&D funding from Royalty Pharma underscores confidence in the program’s commercial potential.
What we're watching
- Clinical Efficacy
- Whether TEV-’408 can sustain its promising early results in the larger Phase 2b trial, particularly for patients with extensive vitiligo.
- Market Differentiation
- How Teva positions TEV-’408 against existing and emerging treatments for vitiligo, given its quarterly dosing advantage.
- Pipeline Progress
- The pace at which Teva advances TEV-’408 in other indications, such as celiac disease, where it has already received Fast Track designation.
Related topics